z-logo
open-access-imgOpen Access
PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
Author(s) -
Chung-Yi Chang,
Yi-Chun Lai,
Yiqun Wei,
ChungYu Chen,
ShihChieh Chang
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s290445
Subject(s) - medicine , lung cancer , immunohistochemistry , epidermal growth factor receptor , oncology , adenocarcinoma , cancer , exon , cancer research , gefitinib , mutation , pathology , gene , biology , biochemistry
Epidermal growth factor receptor (EGFR) mutations are most common in Eastern Asia, and frequencies of 30-50% have been reported. EGFR-tyrosine kinase inhibitors (TKIs) are recommended as first-line therapeutic options for non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. Several immune checkpoint inhibitors have been successful in improving the outcomes of advanced lung cancer. The expression of programmed cell death-ligand 1 (PD-L1) on tumor cells plays an important role in predicting the efficacy of programmed cell death protein 1/PD-L1 inhibitors. The role of PD-L1 expression in tumors with EGFR mutation and its influence on clinical outcomes remain controversial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here